Meet Acesion at these events
- 31 Aug - 4 Sep 2019: ESC Conference, Paris, France.
Acesion is participating with a delegation and present 4 posters on the Saturday 31st Aug session, including two posters on the clinical candidate AP30663:
P699: Mechanisms of action of the KCa2 negative modulator AP30663, a novel compound in development for treatment of atrial fibrillation in man.
P700: The KCa2 channel inhibitor AP30663 selectively increases atrial refractoriness, converts vernakalant-resistant AF and prevents its reinduction in conscious pigs.
P703: Small conductance Ca2+-activated K+-channel inhibition protects the guinea pig heart from ventricular arrhythmia during hypokalemia whereas dofetilide is pro-arrhythmic.
P698: The KCa2 channel inhibitor AP14145, but not dofetilide or ondansetron, provides functional atrial selectivity in guinea pig hearts.
- 16-18 Nov 2019: AHA Conference, Philadelphia, US
- 10-12 Sep 2019: Nordic Life Science Days, Malmö, Sweden
- 25-26 Sep 2019: Annual Biotech in Europe Forum, Basel, Switzerland
- 11-13 Nov 2019: Bio Europe, Hamburg, Germany
Acesion Pharma receives 5M DKK from Innovation Fund Denmark to support human Proof-of-Concept study in Atrial Fibrillation
- 12 March 2019 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces that Innovation Fund Denmark has granted the Company 4,965,000 DKK from the Fund's 'Innobooster' program. The Grant will support the conduction of Acesion's first study in patients with AF. Following a successful Phase I study in healthy volunteers in 2018, Acesion will initiate a Phase II study in the second quarter of 2019 to obtain clinical proof-of-concept for its drug for IV cardioversion of AF to normal sinus rhythm.
Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation
- 05 November 2018 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound AP30663. The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.
Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation
- 12 March 2018 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has commenced the clinical study for its lead compound AP30663.
Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation
- 08 February 2018 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018. Acesion Pharma also announces the appointment of internationally renowned AF experts as scientific advisors.
Acesion Pharma has won the prize as EY Entrepreneur of the Year 2016 in lifescience
- 25 November 2016
Acesion Pharma has won the prize as EY Entrepreneur of the Year 2016 among the nominated Danish Lifesciences companies. The award was received by founders Morten Grunnet and Ulrik Sørensen, and recognizes the results that have been achieved by the Acesion team in the years since Acesion was founded in 2011. There is more about the award here.
Today more than 60 countries worldwide are participating in the EY Entrepreneur Of The Year. EY Entrepreneur Of The Year is the only global business recognition program held on six continents in more than 60 countries and more than 145 cities around the world.
Acesion Pharma recruits an experienced life science Chief Finacial Officer
- 15 November 2016 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), today announced that it has recruited Jakob Dynnes Hansen as its Chief Financial Officer to succeed Herik Moltke, who will continue as CFO of Scandinavian Micro Biodevices that was recently acquired by Zoetis.
Jakob joins Acesion from Evolva, a Swiss biotech company, where he has been CFO since 2007 and where he played a key role in the company's public listing in 2009 and subsequent public financings. Prior to that Jakob was CFO of Nuevolution A/S and Zealand Pharma A/S and had senior roles at a Scandinavian investment bank and at Novo Nordisk A/S. Jakob will also continue to perform srvices for Evolva while the company is transitioning to a new CFO.
Acesion Pharma raises 9.1 million EUR in first closing of new funding from Novo Seeds and Wellcome Trust
- 01 November 2016 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), today announced that it has raised 9.1 million EUR (10 million USD)in a first closing of a new investment round. The round includes current investors Wellcome Trust Ltd. and Novo Seeds, the early stage investment arm of Novo A/S. Wellcome Trust grants its funding in the form of a Translational Award and thereby continues on the Seeding Drug Discovery Initiative Award that it granted to Acesion in 2013.
Acesion Pharma appoints experienced CMC executive Breian Knudsen as VP CMC
- 01 October 2016 » Read the full press release as PDF
COPENHAGEN, Denmark - Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Breian Knudsen, MSc Pharm, as Vice President Chemistry, Manufacturing and Controls.
Breian has extensive experience in developing and managing the manufacture of drug substance and drug product at various companies including Leo Pharma, Ferrosan, Novo Nordisk, LifeCycle Pharma and Veloxis Pharmaceuticals.
Before joining Acesion Pharmaceuticals, Breian was Vice President Technical Operations at Veloxis being responsible for supplying Veloxis and its business partners with drug products including clinical trial materials and commercial product manufactured according to GMP. He is very familiar with selecting and managing contract manufacturing organizations as well as managing relationships with external partners. Breian has a Master of Science degree in Pharmacy from the Royal Danish School of Pharmacy.
Acesion Pharma appoints experienced clinical leader Christina Sylvest as SVP acute cardioversion
- 01 August 2016 » Read the full press release as PDF
COPENHAGEN, Denmark - Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Christina Sylvest, MSc Pharm, as Senior Vice President Acute Cardioversion.
Christina Sylvest has a track record of driving successful clinical development and development programmes. Her appointment comes as Acesion accelerates the preclinical development of its first development candidate for the acute cardioversion of AF.
Christina Sylvest has more than 20 years experience of clinical operations and project management leading global and local Phase I-IV clinical programmes with accountability to CEOs and Boards of Directors. Prior to joining Acesion, Sylvest was responsible for Veloxis Pharmaceuticals A/S (previously Life Cycle Pharma A/S) Phase I-IV clinical operational activities both in Europe and in the US. Prior to Veloxis, Sylvest worked in various management roles in clinical development at Rheoscience A/S, Novo Nordisk A/S and Ferring Pharmaceuticals A/S.
Acesion Pharma appoints experienced industry leader Frans Wuite as CEO
- 13 April 2016 » Read the full press release as PDF
Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Frans Wuite, MD, MBA, as Chief Executive Officer and Ulrik Sørensen, PhD, as Chief Operating Officer.
Frans Wuite has a track record of driving successful clinical development and commercialization programmes. His appointment comes as Acesion accelerates the preclinical development of its first development candidate for the acute cardioversion of AF.
Dr Wuite has more than 25 years pharmaceutical industry experience encompassing leadership roles in start-ups through to large, international companies. Prior to joining Acesion, Wuite led Oncos Therapeutics, a clinical stage cancer immunotherapy company which was successfully merged with Targovax in 2015. Wuite is a board director of Healthcap VII GP S.A. and Herantis Pharma Ltd (HRTIS).
Ulrik Sørensen, the founding CEO of Acesion since 2011, has successfully raised substantial funding from Danish and international investors, including Wellcome Trust, Novo and Broadview Ventures and together with co-founder and CSO Morten Grunnet, built Acesion Pharma into a pharmaceutical company with a portfolio of first-in-class, small molecule drugs for the treatment of atrial fibrillation.
Wellcome Trust Ltd. converts part of the Wellcome Trust Award and becomes shareholder in Acesion Pharma ApS
- 11 May 2015
On 17 June 2013 Acesion Pharma announced that the company had received a 27.9 million DKK (3.7 million EUR) Seeding Drug Discovery Strategic Award from the UK based Wellcome Trust to fund the development of a novel drug for the acute treatment of atrial fibrillation (AF). The award is a convertible loan which Wellcome Trust has now wished to partly convert into shares in Acesion Pharma with the intention of converting the remainder of the released loan in future equity rounds.
In the present transaction Wellcome Trust has converted an undisclosed but substantial part of the released loan capital thereby becoming a major shareholder in Acesion Pharma. The executive management and Board of Directors in Acesion Pharma are very pleased about this further commitment from the Wellcome Trust and look forward to working even closer together with the Trust in the effort to bring an acute cardioversion drug forward and ready for clinical development and testing in human.
Press release: Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures
- 17 December 2014 » Read the full press release as PDF
Acesion Pharma, a Danish biotech company developing novel therapeutic treatments for atrial fibrillation (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity investment round. The round includes Boston-based Broadview Ventures as a new investor and current investor Novo Seeds.
AF is the most common type of cardiac arrhythmia and is characterized by an irregular and abnormally high frequency in the upper chambers of the heart, the atria. AF is associated with impaired quality of life, increased rate of hospitalization, and increased risk of stroke and death. AF is often treated acutely with electrical shock to bring the heart back to its normal rhythm and existing drug therapies have limited efficacy and/or are often associated with risk of serious adverse effects. There is a great need for more efficacious and safer drugs for the medical treatment of AF.
Acesion Pharma is developing a small molecule-based acute treatment of AF, a program funded by the Wellcome Trust Ltd. Within this program Acesion Pharma expects to select a development candidate in 2015.
In addition, Acesion Pharma is developing a chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm (maintenance therapy). The new investment from Novo Seeds and Broadview Ventures will specifically fund the development of the chronic treatment of AF, a program that has been supported to date with funding from the Danish government through the "Innovation Fund Denmark" initiative.
Press release: Acesion Pharma appoints Ingelise Saunders as new Chairman of the Board
- 25 August 2014 » Read the full press release as PDF
The Danish biotech company Acesion Pharma ApS announces that it has with effect from 1 August 2014 appointed Ingelise Saunders as new Chairman of the Board of Directors.
Ingelise Saunders has more than 35 years of experience in the biotech and pharmaceutical industry. Until September 2013 she was CEO of the Swedish life science investment company SLS Invest AB. Prior to that she was CEO in three privately owned Danish Biotech companies, among these Action Pharma A/S, which was sold to Abbott in 2012. Ingelise Saunders is today a Director of the Board of Leo Pharma A/S and Chairman of the Board of MinervaX ApS. Ingelise will bring to Acesion Pharma the necessary business expertise to ensure the transition of Acesion Pharma's preclinical assets into clinical development and commercialization.
As a further change in the Board of Directors from 1 August 2014, Carsten Schou is replacing Frank Knudsen as representative from the investor SEED Capital.
Press release: Acesion Pharma and university partner receives 14 mio DKK (2.6 mio USD) in funding from The Danish National Advanced Technology Foundation (Højteknologifonden)
- 16 December 2013 » Read the full press release (in Danish)
Acesion Pharma has, together with the Danish National Research Foundation Centre for Cardiac Arrhythmia at Copenhagen University, received a grant from The Danish National Advanced Technology Foundation. The investment is in a four year program to develop novel drugs against atrial fibrillation, and the foundation grant covers half of the total budget of 28 mio DKK.
The Danish National Advanced Technology Foundation is founded by the Danish government and has the general objective to enhance growth by supporting strategic and advanced technological priorities within the fields of research and innovation.
Press release: Acesion Pharma receives Wellcome Trust Award for their atrial fibrillation program and raises in total 35.1 mio DKK (4.7 mio EUR)
- 17 June 2013 » Read the full press release as PDF
The Danish biotech company Acesion Pharma announces that it has received a 27.9 million DKK (3.7 million EUR) Seeding Drug Discovery Award from the UK based Wellcome Trust to fund the development of a novel drug for the acute treatment of atrial fibrillation (AF).
AF is the most common type of cardiac arrhythmia, or irregular heartbeat, and affects about 1% of the population. There is high unmet need for better drugs for the medical treatment of AF as current drugs are ineffective in many cases and associated with unwanted side effects.
Acesion Pharma aims to develop more efficacious and safer drugs for AF based on a novel concept of inhibiting a type of ion channel in heart cells that is involved in generating the electrical signals that regulate the heart's rhythm. Blocking these channels, known as SK channels, with a targeted drug constitutes a new and promising approach for developing improved treatments of AF. The Award from the Wellcome Trust will fund a program to identify a novel and improved drug to restore the normal rhythm of the heart in a one-off treatment for patients with on-going AF.